Omnipod® 5 in the Real World
What do you get with data from thousands of Omnipod 5 users?
Incredible results! In a real-world study with data from tens of thousands of Omnipod 5 users, we learned how the Omnipod 5 System is performing in people’s everyday lives. This means at work, in school, at birthday parties, and on vacations. Learn more about the results and the Omnipod 5 features that make them possible below.
On average, users who set their Target Glucose to 110mg/dL spent nearly 70% time in range1 and 1.12% time below range.2
No need to disconnect
The Pod and sensor communicate with each other on-body including during water activities*, sports, and other moments tubed pump users usually disconnect for.†
Time in Range Tip
Users spent 94% time in Automated Mode.3
Make sure your Pod and sensor are within line of sight so they can “see” each other. This maximizes time spent in Automated Mode.
Customizable Target Glucose
Omnipod 5 offers five different customizable Target Glucose Settings, letting you personalize your insulin delivery.
Time in Range Tip
Users who selected 110mg/dL as their Target Glucose setting spent the highest amount of Time in Range.4
Talk to your doctor to determine which Target Glucose settings are best for you.
Adaptive Basal Rate
The Omnipod 5 System updates your Adaptive Basal Rate with each Pod change to help protect against highs and lows, day and night.5,6
Time in Range Tip
Users who bolused at least 4 times per day spent more Time in Range.7
The Omnipod 5 System uses your average total daily insulin to understand your unique insulin needs. Total daily insulin includes both basal and bolus doses.
Omnipod allows me the freedom to enjoy physical activities. I can swim* and dance without having to disconnect…it lets me stay focused on what I’m doing.
Madison B.
Podder since 2021
Omnipod 5 has allowed me to get a good night sleep. That's the first time I can say that in a long time.
Alvin
Podder since 2017
Curious to see your own results?
It’s simple.
Click below to log into your Glooko account and discover your Time in Range, time spent in Automated Mode, and more.
Want to learn more?
Check out our most-loved Omnipod 5 resources
*The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller is not waterproof.
†Device components including the Pod, CGM transmitter, and CGM sensor may be affected by strong radiation or magnetic fields. Device components must be removed (and the Pod and CGM sensor should be disposed of) before X-ray, Magnetic Resonance Imaging (MRI), or Computed Tomography (CT) scan (or any similar test or procedure). In addition, the Controller and smartphone should be placed outside of the procedure room. Exposure to X-ray, MRI, or CT, treatment can damage these components. Check with your healthcare provider on Pod removal guidelines.
1. Forlenza G, et al. Diabetes Technol Ther (2024). Real-world data from 37,640 Omnipod 5 users with type 1 diabetes at the Target Glucose of 110 mg/dL had a median TIR (70-180 mg/dL) of 68.8%. Omnipod 5 results based on users with ≥90 days CGM data, ≥75% of days with ≥220 readings available.
2. Forlenza G, et al. Diabetes Technol Ther (2024). Real-world data from 37,640 individuals with type 1 diabetes using Omnipod 5 at the Target Glucose of 110 mg/dL had a median TBR (<70 mg/dL) of 1.12%. Omnipod 5 results based on users with ≥90 days CGM data, ≥75% of days with ≥220 readings available.
3. Forlenza G, et al. Diabetes Technol Ther (2024). 9,028 children and adolescents with type 1 diabetes using Omnipod 5 at the 110 mg/dL glucose target spent a median of 94.6% time in Automated Mode. 28,612 adult Omnipod 5 users with type 1 diabetes utilizing the 110 mg/dL glucose target spent a median of 94.1 time in Automated Mode. Omnipod 5 results based on users with ≥90 days CGM data, ≥75% of days with ≥220 readings available.
4. Forlenza G, et al. Diabetes Technol Ther (2024). Real-world data from 69,902 Omnipod 5 users with type 1 diabetes. Median percentage of time in range (TIR; 70–180 mg/dL) was 68.8%, 61.3%, and 53.6% for users with average glucose targets of 110, 120, and 130–150 mg/dL, respectively. Omnipod 5 results based on users with ≥90 days CGM data, ≥75% of days with ≥220 readings available.
5. Study in 240 people with T1D aged 6 - 70 years involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average overnight time (12AM-6AM) with high blood glucose in adults/adolescents and children for standard therapy vs. Omnipod 5 = 32.1% vs. 20.7%; 42.2% vs. 20.7%. Average day time (6AM-12AM) with high blood glucose in adults/adolescents and children for standard therapy vs. Omnipod 5 = 32.6% vs. 26.1%; 46.4% vs. 33.4%. Median overnight time (12AM-6AM) with low blood glucose in adults/adolescents and children for standard therapy vs. Omnipod 5 = 2.07% vs. 0.82%; 0.78% vs. 0.78%. Median day time (6AM-12AM) with low blood glucose in adults/adolescents and children for standard therapy vs. Omnipod 5 = 1.91% vs. 1.08%; 1.17% vs. 1.62%. Brown et al. Diabetes Care (2021).
6. Study in 80 people with T1D aged 2 - 5.9 yrs involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average time with high blood glucose overnight from CGM in standard therapy vs. Omnipod 5 = 38.4% vs. 16.9%. Average time with high blood during daytime from CGM in standard therapy vs. Omnipod 5 = 39.7% vs. 33.7%. Average time with low blood glucose overnight from CGM in standard therapy vs. Omnipod 5 = 3.41% vs. 2.13%. Average time with low blood glucose during daytime from CGM in standard therapy vs. Omnipod 5 = 3.44% vs. 2.57%. Sherr JL, et al. Diabetes Care (2022).
7. Forlenza G, et al. Diabetes Technol Ther (2024). Real-world data from 37,640 Omnipod 5 users with type 1 diabetes at the Target Glucose of 110 mg/dL was analyzed based on whether the user bolused ≥4x per day or <4x per day. Users who bolused ≥4x per day (n=25,121) had a TIR (70-180 mg/dL) of 72.4%. Users who bolused <4x per day (n=12,519) had a TIR (70-180 mg/dL) of 59.9%. Omnipod 5 results based on users with ≥90 days CGM data, ≥75% of days with ≥220 readings available.
Risk Statement
The Omnipod® 5 Automated Insulin Delivery System is indicated for use by individuals with Type 1 diabetes mellitus in persons 2 years of age and older and type 2 diabetes mellitus in persons 18 years of age and older. The Omnipod® 5 System is intended for single patient, home use and requires a prescription. The Omnipod® 5 System is compatible with the following U-100 insulins: NovoLog®, Humalog®, and Admelog®.
The Omnipod® 5 ACE Pump (Pod) is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The Omnipod® 5 ACE Pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. SmartAdjust™ technology is intended for use with compatible integrated continuous glucose monitors (iCGM) and alternate controller enabled (ACE) pumps to automatically increase, decrease, and pause delivery of insulin based on current and predicted glucose values. The Omnipod® 5 SmartBolus Calculator is intended to calculate a suggested bolus dose based on user-entered carbohydrates, most recent sensor glucose value (or blood glucose reading if using fingerstick), rate of change of the sensor glucose (if applicable), insulin on board (IOB), and programmable correction factor, insulin to carbohydrate ratio, and target glucose value.
Warning: SmartAdjust™ technology should NOT be used by anyone under the age of 2 years old. SmartAdjust™ technology should also NOT be used in people who require less than 5 units of insulin per day as the safety of the technology has not been evaluated in this population.
The Omnipod® 5 System is NOT recommended for people who are unable to monitor glucose as recommended by their healthcare provider, are unable to maintain contact with their healthcare provider, are unable to use the Omnipod® 5 System according to instructions, are taking hydroxyurea as it could lead to falsely elevated CGM values and result in over-delivery of insulin that can lead to severe hypoglycemia, and do NOT have adequate hearing and/or vision to allow recognition of all functions of the Omnipod® 5 System, including alerts, alarms, and reminders. Device components including the Pod, CGM transmitter, and CGM sensor must be removed before Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scan, or diathermy treatment. In addition, the Controller and smartphone should be placed outside of the procedure room. Exposure to MRI, CT, or diathermy treatment can damage the components. Visit www.omnipod.com/safety for additional important safety information.
Warning: DO NOT start to use the Omnipod® 5 System or change settings without adequate training and guidance from a healthcare provider. Initiating and adjusting settings incorrectly can result in over-delivery or under-delivery of insulin, which could lead to hypoglycemia or hyperglycemia.